Why in news?
Indian scientists developed the country's first indigenous African swine fever vaccine. The live attenuated candidate uses a locally producible cell-culture platform. Laboratory and controlled field studies reported protection against severe disease. Wider use still depends upon licensing, production and supervised deployment.
Background
African swine fever (ASF) is a severe viral disease of domestic and wild pigs. The African swine fever virus belongs to a distinctive deoxyribonucleic acid virus family. Some outbreaks kill almost every susceptible pig in an affected group.
The disease was first described in Kenya during the early twentieth century. It remained established across parts of Africa before spreading into Europe and Asia. Genotype II drove much of the recent international expansion.
India confirmed its first outbreaks during 2020, initially in Assam and Arunachal Pradesh. The disease then affected several states and Union territories, causing serious losses among northeastern pig-rearing households.
The World Organisation for Animal Health lists ASF for mandatory international notification. It does not infect humans and poses no direct human-health risk. However, contaminated pork can spread the virus to pigs through untreated food waste.
How the virus spreads
Infected pigs release virus through blood, tissues and bodily fluids, allowing direct contact to spread infection rapidly within farms. Wild boar may maintain transmission in some landscapes.
The virus also survives on equipment, clothing, vehicles and animal products, while untreated kitchen waste creates another route. Some soft ticks support a separate transmission cycle in particular regions.
Clinical signs can include high fever, weakness, internal bleeding and sudden death. These signs resemble other swine diseases, so laboratory confirmation is essential. There is no reliable curative treatment for infected animals.
Control traditionally relies upon rapid reporting, movement restrictions and humane culling. Cleaning, safe disposal and farm biosecurity remain central, while vaccination would complement rather than replace them.
The Indian development
The Indian Council of Agricultural Research (ICAR) led the national project. Its National Institute of High Security Animal Diseases in Bhopal developed the vaccine candidate. High-containment facilities were necessary because the virus remains unusually resilient.
Scientists weakened a genotype II virus through targeted gene deletions. This live attenuated virus can stimulate immunity without producing ordinary severe disease under tested conditions. The design used the widely available MA-104 cell line for production.
Researchers evaluated sterility, genetic stability, safety and immune responses. They also examined protection after challenge and the possibility of renewed virulence. Field validation involved the Department of Animal Husbandry and Dairying.
The government described two one-millilitre intramuscular doses for healthy pigs older than eight weeks, separated by fourteen days. This reported research protocol is not unsupervised treatment advice.
Why the cell line matters
A vaccine virus must grow consistently in cells suitable for manufacturing. Proprietary platforms can restrict technology transfer and raise production costs. A widely available cell line may support larger domestic production.
Cell growth alone does not guarantee an affordable finished vaccine. Manufacturers require validated seed stocks and cold chains, while every batch must maintain attenuation and potency.
Commercially licensed live vaccines have already appeared in Vietnam. The Indian candidate is therefore not the world's first ASF vaccine. Its verified distinction is being India's first indigenous candidate of this kind.
Benefits and scientific risks
An effective domestic vaccine could reduce mass mortality and livelihood losses. It may also lower repeated culling costs and supply disruption. Regional access matters because smallholders cannot absorb repeated herd destruction.
Live attenuated vaccines can generate strong immunity because the weakened virus briefly replicates. That feature demands stability testing and monitoring for prolonged circulation or renewed virulence.
Field virus strains may vary, while vaccines can complicate disease surveillance. Tests should distinguish vaccinated from infected animals, because otherwise trade and outbreak investigation become harder.
Vaccinating sick animals or using an incorrect schedule can undermine protection, while unauthorised products create additional risk. Veterinary supervision and traceable distribution are therefore essential.
Economic and policy implications
Government estimates place early Assam losses near โน276 crore. Mizoram reported losses approaching โน982 crore through 2025 and thousands of affected households. These estimates describe different periods and should not be combined casually.
Compensation encourages farmers to report disease rather than hide deaths. Surveillance must include farms, markets, transport routes and wild pigs. Border cooperation is also important because animals and products move across states and countries.
Vaccination plans should prioritise risk and maintain records by animal and location. Authorities must continue testing suspected outbreaks despite vaccination. Transparent publication of trial design and adverse events would strengthen public confidence.
Conclusion
The indigenous vaccine could transform ASF control if later deployment remains safe and accountable. It must reinforce surveillance, biosecurity and farmer support rather than substitute for them.